Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine.

ABSTRACT:

Objectives

To examine the differences in durability and its determinants of humoral immunity following 2- and 3-dose COVID-19 vaccination.

Methods

Throughout the pandemic, we evaluated the anti-spike IgG antibody titers of 2- and 3-dose mRNA vaccine recipients over time among the staff of a medical and research center in Tokyo. Linear mixed models were used to estimate trajectories of antibody titers from 14 to 180 days after the last immune-conferred event (vaccination or infection) and compare antibody waning rates across prior infection and vaccination status, and across background factors in infection-naïve participants.

Results

A total of 6901 measurements from 2964 participants (median age, 35 years; 30% male) were analyzed. Antibody waning rate (percentage per

SUBMITTER: Yamamoto S 

PROVIDER: S-EPMC10207835 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature